Margaret Fischl | Academic Influence

Margaret Fischl's AcademicInfluence.com Rankings

Margaret Fischl

Philosophy

#6579

World Rank

#9636

Historical Rank

Logic

#4427

World Rank

#5716

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Margaret Fischl's Degrees

Doctorate Medicine University of Miami

Why Is Margaret Fischl Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Margaret Fischl is an American physician, HIV/AIDS researcher, and professor of medicine at the University of Miami. She is notable for being one of the first researchers to discover the effectiveness of the antiretroviral medication azidothymidine in treating patents with HIV/AIDS, as well as for helping build the University of Miami's AIDS Clinical Research Unit, of which she served as director. Fischl attended the University of Miami Miller School of Medicine, from which she earned her M.D. in 1976, and later served her residency at Jackson Memorial Hospital in Miami.

(See a Problem?)

Margaret Fischl's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. (1987) (2759)
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. (1997) (2544)
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. (1987) (1503)
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. (1997) (1316)
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. (2000) (1117)
Antiretroviral Treatment of Adult HIV Infection (2008) (1090)
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. (1998) (1006)
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008) (828)
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. (2002) (777)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. (2006) (769)
ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX (1986) (733)
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. (2004) (730)
Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel (1996) (651)
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. (1998) (586)
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial (1990) (532)
PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT) (1988) (464)
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. (1996) (451)
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. (1992) (383)
Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. (1984) (368)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. (2003) (357)
Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. (1990) (350)
Recombinant human erythropoietin for patients with AIDS treated with zidovudine. (1990) (343)
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. (2009) (332)
Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state. (1983) (324)
RESPONSE OF HUMAN-IMMUNODEFICIENCY-VIRUS-ASSOCIATED NEUROLOGICAL DISEASE TO 3'-AZIDO-3'-DEOXYTHYMIDINE (1987) (321)
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. (2009) (321)
Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection (1996) (318)
Evaluation of heterosexual partners, children, and household contacts of adults with AIDS. (1987) (310)
Glomerular lesions in the acquired immunodeficiency syndrome. (1984) (307)
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome (1990) (303)
Monitoring Plasma HIV-1 RNA Levels in Addition to CD4+ Lymphocyte Count Improves Assessment of Antiretroviral Therapeutic Response (1997) (289)
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. (2004) (283)
An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. (1981) (274)
Zidovudine treatment of the AIDS dementia complex: Results of a placebo‐controlled trial (1993) (274)
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. (1998) (252)
Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. (1992) (246)
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1 (2011) (233)
Safety and Efficacy of Sulfamethoxazole and Trimethoprim Chemoprophylaxis for Pneumocystis carinii Pneumonia in AIDS (1988) (221)
Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. (1994) (205)
Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study (2012) (203)
Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. (1989) (196)
Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. (1988) (193)
Prolonged Zidovudine Therapy in Patients With AIDS and Advanced AIDS-Related Complex (1989) (193)
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. (1992) (189)
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. (2020) (183)
Mothers of infants with the acquired immunodeficiency syndrome. Evidence for both symptomatic and asymptomatic carriers (1985) (181)
Cohort Profile: The Women's Interagency HIV Study (WIHS). (2018) (176)
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. (2011) (173)
Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccine. (2012) (163)
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. (1995) (137)
Combination Therapy with Zidovudine and Didanosine Compared with Zidovudine Alone in HIV-1 Infection (1993) (134)
Use of whole blood methods in assessment of immune parameters in immunodeficiency states. (1987) (133)
Neurologic Disease as the Presenting Manifestation of Acquired Immunodeficiency Syndrome (1987) (121)
Tuberculosis symposium: emerging problems and promise. (1993) (120)
Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease (1995) (116)
Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. (2008) (110)
Impaired Antibody Response to Influenza Vaccine in HIV-Infected and Uninfected Aging Women Is Associated with Immune Activation and Inflammation (2013) (107)
Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy (2015) (107)
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT (2008) (105)
Cytomegalic inclusion virus encephalitis in patients with AIDS: CT, clinical, and pathologic correlation. (1986) (101)
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy (1996) (96)
Population Pharmacokinetics of Nevirapine, Zidovudine, and Didanosine in Human Immunodeficiency Virus-Infected Patients (1999) (95)
Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. (2000) (94)
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. (1994) (94)
ICU survival of patients with the acquired immunodeficiency syndrome (1986) (92)
Racial and Ethnic Differences in Outcome in Zidovudine-Treated Patients With Advanced HIV Disease (1991) (90)
Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260) (2000) (90)
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. (1989) (89)
Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: A meta-analysis (2000) (88)
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. (2014) (87)
Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease (1988) (86)
Immune Exhaustion Occurs Concomitantly With Immune Activation and Decrease in Regulatory T Cells in Viremic Chronically HIV-1–Infected Patients (2010) (86)
Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. (1992) (86)
Decreases in Colonic and Systemic Inflammation in Chronic HIV Infection after IL-7 Administration (2014) (85)
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. (2003) (83)
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). (2006) (80)
Enteric coccidiosis among patients with the acquired immunodeficiency syndrome. (1984) (80)
Salmonella bacteremia as manifestation of acquired immunodeficiency syndrome. (1986) (80)
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta‐analysis of studies of the AIDS Clinical Trials Group (1998) (80)
Zalcitabine Compared with Zidovudine in Patients with Advanced HIV-1 Infection Who Received Previous Zidovudine Therapy (1993) (80)
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. (1998) (78)
A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. (1991) (77)
Immune Activation in HIV-Infected Aging Women on Antiretrovirals—Implications for Age-Associated Comorbidities: A Cross-Sectional Pilot Study (2013) (75)
Predictors of Virologic and Clinical Outcomes in HIV-1Infected Patients Receiving Concurrent Treatment with Indinavir, Zidovudine, and Lamivudine: AIDS Clinical Trials Group Protocol 320 (2001) (75)
Upregulation of IL-21 Receptor on B Cells and IL-21 Secretion Distinguishes Novel 2009 H1N1 Vaccine Responders from Nonresponders among HIV-Infected Persons on Combination Antiretroviral Therapy (2011) (74)
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. (2002) (73)
A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. (2005) (69)
HIV infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine. (2015) (68)
Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels: Results of a Prospective Randomized Trial (AIDS Clinical Trial Group 5125s) (2007) (64)
Evaluation of cerebral mass lesions in acquired immunodeficiency syndrome. (1983) (63)
Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. (1993) (61)
Combination antiretroviral therapy for HIV infection. (1994) (60)
Weekly doxorubicin in the treatment of patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. (1993) (60)
Tuberculous brain abscess and Toxoplasma encephalitis in a patient with the acquired immunodeficiency syndrome. (1985) (59)
Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine (1995) (58)
Kaposi's sarcoma of the tracheobronchial tree. Clinical, bronchoscopic, and pathologic features. (1985) (57)
Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine in Patients with AIDS or AIDS-Related Complex (1993) (54)
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators. (1999) (54)
Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. (2001) (53)
Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies. (2016) (52)
Heterosexual transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. (1985) (52)
Decreased natural cell-mediated cytotoxicity per effector cell in acquired immunodeficiency syndrome. (1985) (51)
Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. (1994) (51)
The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. (1995) (50)
Competing drug–drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 (2000) (49)
Disseminated miliary tuberculosis of the skin in patients with AIDS: report of four cases. (1998) (49)
Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. (1991) (49)
Multidrug-resistant tuberculous meningitis in patients with AIDS. (2003) (48)
Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States Associated Factors, Awareness, and Acceptability (2019) (47)
Fansidar prophylaxis of Pneumocystis pneumonia in the acquired immunodeficiency syndrome. (1986) (45)
Mothers of infants with the acquired immunodeficiency syndrome. Evidence for both symptomatic and asymptomatic carriers. (1985) (45)
Tuberculosis and nontuberculous mycobacteriosis in patients with AIDS. (1988) (44)
A Phase II Study of Recombinant Human Interferon-α2a and Zidovudine in Patients with AIDS-Related Kaposi's Sarcoma (1996) (44)
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysis. (2013) (43)
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. (2007) (43)
Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. (1999) (41)
Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection (1997) (41)
Interferon-α2b With Protease Inhibitor-Based Antiretroviral Therapy in Patients With AIDS-Associated Kaposi Sarcoma: An AIDS Malignancy Consortium Phase I Trial (2006) (41)
Amprenavir in Combination with Lamivudine and Zidovudine versus Lamivudine and Zidovudine Alone in HIV-1-Infected Antiretroviral-Naive Adults (1999) (40)
Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. (1995) (40)
The Effect of Zidovudine Treatment on Serum Neopterin and β2‐Microglobulin Levels in Mildly Symptomatic, HIV Type 1 Seropositive Individuals (1992) (40)
Mutations in HIV-1 Reverse Transcriptase during Therapy with Abacavir, Lamivudine and Zidovudine in HIV-1-Infected Adults with No Prior Antiretroviral Therapy (2002) (39)
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261) (1999) (38)
Impact of aging and HIV infection on serologic response to seasonal influenza vaccination (2018) (37)
Acquired immune deficiency syndrome in low-risk patients. Evidence for possible transmission by an asymptomatic carrier. (1983) (37)
Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test. (2015) (37)
Upper airway obstruction secondary to acquired immunodeficiency syndrome-related Kaposi's sarcoma. (1985) (36)
Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. (1997) (36)
Hepatitis C virus infection in a sexually active inner city population. The potential for heterosexual transmission (1994) (35)
Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study. (2007) (34)
Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age (2017) (34)
High Levels of Inflammatory Cytokines in the Reproductive Tract of Women with BV and Engaging in Intravaginal Douching: A Cross-Sectional Study of Participants in the Women Interagency HIV Study. (2016) (34)
HIV-1 viruses detected during episodic blips following interleukin-7 administration are similar to the viruses present before and after interleukin-7 therapy (2011) (34)
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. (1990) (34)
Bacterial Vaginosis Is Associated with Loss of Gamma Delta T Cells in the Female Reproductive Tract in Women in the Miami Women Interagency HIV Study (WIHS): A Cross Sectional Study (2016) (33)
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. (2014) (33)
ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy (1999) (32)
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen (2007) (32)
Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. Aids Clinical Trials Group Virology Laboratories. (1994) (31)
Disseminated tuberculosis and the acquired immunodeficiency syndrome. (1983) (31)
Analysis of myopathy in a placebo‐controlled zidovudine trial (1997) (31)
Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes. (2011) (29)
Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection. (2013) (28)
Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. (2011) (27)
Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults. (2002) (27)
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202. (2013) (27)
Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials (1994) (27)
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. (1990) (26)
Cumulative Burden of Depression and All-Cause Mortality in Women Living With Human Immunodeficiency Virus (2018) (26)
Azidothymidine in the treatment of AIDS. (1988) (26)
Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. (1995) (25)
The Prevalence and Burden of Non-AIDS Comorbidities among Women living with or at-risk for HIV Infection in the United States. (2020) (24)
AIDS Clinical Trials Group: phase I/II study of combination 2',3'-dideoxycytidine and zidovudine in patients with acquired immunodeficiency syndrome (AIDS) and advanced AIDS-related complex. (1990) (24)
A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy. (2016) (24)
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. (2014) (23)
Interest in Long-Acting Injectable Pre-exposure Prophylaxis (LAI PrEP) Among Women in the Women’s Interagency HIV Study (WIHS): A Qualitative Study Across Six Cities in the United States (2020) (23)
Elevated Plasma Ceramides Are Associated With Antiretroviral Therapy Use and Progression of Carotid Artery Atherosclerosis in HIV Infection (2019) (23)
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. (2012) (23)
Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy (2007) (23)
Antiretroviral therapy in combination with interferon for AIDS-related Kaposi's sarcoma. (1991) (22)
State of antiretroviral therapy with zidovudine (1989) (22)
Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068 (1996) (22)
Increased glucose transporter-1 expression on intermediate monocytes from HIV-infected women with subclinical cardiovascular disease (2017) (21)
Integration of Atazanavir into an Existing Liquid Chromatography UV Method for Protease Inhibitors: Validation and Application (2007) (21)
HIV-1 inhibition by azidothymidine in a concurrently randomized placebo-controlled trail. (1988) (21)
A cross-sectional study of bacterial vaginosis, intravaginal practices and HIV genital shedding; implications for HIV transmission and women's health (2015) (21)
Cervical cancer screening intervals and management for women living with HIV: a risk benchmarking approach (2017) (20)
Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects (2003) (19)
Loss of Intra‐Epithelial Endocervical Gamma Delta (GD) 1 T Cells in HIV‐Infected Women (2016) (19)
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. (2003) (19)
Seroprevalence and Risks of HIV Infections in Spouses of Persons Infected with HIV (1988) (19)
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. (2000) (18)
An evaluation of oral ulcers in patients with AIDS and AIDS-related complex. (1993) (18)
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. (1997) (18)
Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience (2008) (18)
DECLINING INCIDENCE OF KAPOSI'S SARCOMA IN AIDS CLINICAL TRIAL GROUP (ACTG) TRIALS (1998) (17)
Pharmacokinetics of Indinavir and Nelfinavir in Treatment-Naive, Human Immunodeficiency Virus-Infected Subjects (2004) (16)
Combination therapy with recombinant human soluble CD4-immunoglobulin G and zidovudine in patients with HIV infection: a phase I study. (1995) (16)
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. (1998) (16)
Assessing the Impact of Substance use and Hepatitis Coinfection on Atazanavir and Lopinavir Trough Concentrations in HIV-Infected Patients During Therapeutic Drug Monitoring (2007) (15)
A Qualitative Exploration of Women's Interest in Long-Acting Injectable Antiretroviral Therapy Across Six Cities in the Women's Interagency HIV Study: Intersections with Current and Past Injectable Medication and Substance Use. (2021) (15)
Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. (1995) (15)
A bio-behavioral intervention to decrease intravaginal practices and bacterial vaginosis among HIV infected Zambian women, a randomized pilot study (2017) (15)
The AIDS Clinical Trials Group (1990) (15)
Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: AIDS Clincal Trial Group 068. (1996) (14)
Weight and body mass index change after switching to integrase inhibitors or tenofovir alafenamide among women living with HIV. (2020) (13)
A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir (2002) (13)
Phase I Study of Interferon Alpha and AZT in Patients with AIDS Related Kaposi’s Sarcoma (1988) (13)
Detection of Replication-Competent Human Immunodeficiency Virus Type 1 (HIV-1) in Cultures from Patients with Levels of HIV-1 RNA in Plasma Suppressed to Less Than 500 or 50 Copies Per Milliliter (2002) (13)
Multisite Study of Women Living With HIV's Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy. (2020) (13)
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. (1999) (13)
Pharmacokinetics of Nelfinavir and Efavirenz in Antiretroviral-Naïve, Human Immunodeficiency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (13)
Impact of vaginal microbiome communities on HIV antiretroviral-based pre-exposure prophylaxis (PrEP) drug metabolism (2020) (12)
Report of 24 cases of Listeria monocytogenes infection at the University of Miami Medical Center. (1997) (12)
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants (2017) (12)
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. (2016) (12)
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. (2007) (12)
Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study (2018) (12)
Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection? (2001) (12)
Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV (2020) (12)
The Impact of Cumulative Depression along the HIV Care Continuum in Women Living with HIV during the Era of Universal Antiretroviral Treatment (2019) (12)
Human Immunodeficiency Virus (HIV) among Female Prostitutes in South Florida (1987) (12)
HIV and symptoms of depression are independently associated with impaired glucocorticoid signaling (2018) (11)
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202 (2019) (11)
Smoking, HIV, and risk of pregnancy loss (2017) (11)
Associations of Plasma Cytokine and Microbial Translocation Biomarkers With Immune Reconstitution Inflammatory Syndrome (2017) (11)
Antiviral Therapy for HIV Infection (1997) (11)
The challenge of HIV-1 genetic diversity: discordant CD4+ T-Cell count and viral load in an untreated patient infected with a subtype F strain. (2009) (11)
Mothers of infants with the acquired immunodeficiency syndrome (AIDS): outcome of subsequent pregnancies [abstract] (1985) (10)
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. (2002) (10)
Addressing intravaginal practices in women with HIV and at-risk for HIV infection, a mixed methods pilot study (2017) (10)
A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. (2010) (10)
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. (2010) (10)
Epidemiological evidence that common HPV types may be common because of their ability to evade immune surveillance: Results from the Women's Interagency HIV study (2020) (10)
Prevalence and 1-year incidence of frailty among women with and without HIV in the Women's Interagency HIV Study. (2019) (10)
Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping. (1998) (10)
Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017 (2019) (9)
Adolescent girls and young women living with HIV: preconception counseling strategies (2017) (9)
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. (2004) (9)
The Tat and C2-V3 envelope genes in the molecular epidemiology of human immunodeficiency virus-1. (1996) (9)
Effect of IL-7 Therapy on Phospho-Ribosomal Protein S6 and TRAF1 Expression in HIV-Specific CD8 T Cells in Patients Receiving Antiretroviral Therapy (2018) (9)
Behaviorally and perinatally HIV-infected young women: targets for preconception counseling (2017) (9)
Safety and Efficacy of zidovudine in asymptomatic HIV infected individuals withless than 500 CD4+ cells/mm3. (1990) (8)
A MULTICENTER, PHASE II/III STUDY OF ATRAGEN™ (Tretinoin Liposomal) IN PATIENTS WITH AIDS-ASSOCIATED KAPOSI'S SARCOMA: 14 (1997) (8)
A multi-site study of women living with HIV's perceived barriers to, and interest in, long-acting injectable anti-retroviral therapy. (2020) (8)
Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections (1996) (7)
Prevention of acquired immunodeficiency syndrome. (1983) (7)
A Phase I Study of Recombinant Human Interferon‐α2a or Human Lymphoblastoid Interferon-αn1 and Concomitant Zidovudine in Patients with AIDS‐Related Kaposi's Sarcoma (1991) (7)
Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease. (2004) (7)
A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen (2010) (7)
Erratum: A Randomized Trial of 2 Different 4-Drug Antiretroviral Regimens versus 3-Drug Regimen, in Advanced Human Immunodeficiency Virus Disease (Journal of Infectious Diseases (September 01, 2003) 188 (625-34)) (2003) (7)
T Cell Activation Markers and African Mitochondrial DNA Haplogroups among Non-Hispanic Black Participants in AIDS Clinical Trials Group Study 384 (2012) (7)
Incarceration and Number of Sexual Partners After Incarceration Among Vulnerable US Women, 2007-2017. (2020) (6)
Therapeutic Drug Monitoring of Protease Inhibitors and Efavirenz in HIV-Infected Individuals With Active Substance-Related Disorders (2011) (6)
Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women (2018) (6)
Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebo-controlled trials. (1996) (6)
Zidovudine: clinical experience in symptomatic HIV disease. (1989) (6)
Primary HPV and Molecular Cervical Cancer Screening in US Women Living with HIV. (2020) (6)
Incident Non-AIDS Comorbidity Burden among Women with or at-risk for HIV in the U.S. (2021) (5)
Incidence and Prevalence of Incarceration in a Longitudinal Cohort of Women at Risk for Human Immunodeficiency Virus in the United States, 2007-2017. (2021) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Effect of Food on the Steady-State Pharmacokinetics of Delavirdine in Patients with HIV Infection (2003) (5)
AN ACQUIRED IMMUNODEFICIENCY SYNDROME AMONG HAITIANS: AN UPDATE (1984) (5)
Associations between Antiretrovirals and Cognitive Function in Women with HIV (2020) (5)
Prevalence of HTLV-III/LAV antibodies among Haitians. (1985) (5)
A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi's sarcoma. AIDS Clinical Trials Group. (1996) (5)
Interferon Alfa-N1 WellferonR in Kaposi’s Sarcoma: Single Agent or Combination with Vinblastine (1987) (5)
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. (2007) (4)
Effects of Health Insurance Interruption on Loss of Hypertension Control in Women With and Women Without HIV. (2017) (4)
Use of Danozol in Autoimmune Thrombocytopenia Associated with the Acquired Immunodeficiency Syndrome (1985) (4)
Contributions of HIV, HCV, and traditional vascular risk factors to peripheral artery disease in women. (2019) (4)
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. (1996) (4)
Food insecurity and frailty among women with and without HIV in the United States: a cross‐sectional analysis (2021) (4)
Long-Acting Injectable ART and PrEP Among Women in Six Cities Across the United States: A Qualitative Analysis of Who Would Benefit the Most (2021) (4)
Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women with HIV. (2020) (4)
Safety and effi cacy of the peptide-based therapeutic vaccine for HIV-1 , Vacc-4 x : a phase 2 randomised , double-blind , placebo-controlled trial (2014) (4)
Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). (1994) (4)
Treatment and prophylaxis of Pneumocystis carinii pneumonia. (1988) (4)
Isolation and Flow Cytometric Analysis of Human Endocervical Gamma Delta T Cells. (2017) (4)
Longitudinal assessment of abnormal Papanicolaou test rates among women with HIV. (2020) (4)
Heterosexual Transmission of Acquired Immunodeficiency Syndrome-Reply (1987) (4)
Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Women (2017) (4)
Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202 (2013) (3)
Heterogeneity and Public Health in the Global HIV / AIDS Epidemic (2001) (3)
Predicting relapse in acute bronchial asthma. (1982) (3)
Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy (2018) (3)
Evaluation of household contacts of adult patients with the acquired immunodeficiency syndrome [abstract] (1985) (3)
Elevated CD4+ T-cell glucose metabolism in HIV+ women with diabetes mellitus (2022) (3)
Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women. (2021) (2)
A therapeutic HIV-1 vaccine reduces markers of systemic immune activation and latent infection in patients under highly active antiretroviral therapy. (2020) (2)
EFFICACY AND TOXICITIES OF COMBINATION ANTIRETROVIRAL THERAPIES (1994) (2)
Heterosexual and Household Transmission of the Human T‑lymphotropic Virus Type II (1986) (2)
Immunomodulation of Patients with AIDS Related Complexes (ARC) During Therapy with Recombinant Interferon Gamma (IFNG) (1988) (2)
Mental Health Mediates the Association Between Gender-Based Violence and HIV Treatment Engagement in US Women (2021) (2)
Rapid Point-of-Care Test Kit for Bacterial Vaginosis: Detection of Vaginolysin and Clue Cells Using Paper Strips and a Smartphone. (2022) (2)
Treatment of HIV disease in 1993/1994. (1993) (2)
Human Lymphoblastoid Interferon Treatment of Kaposi's Sarcoma in Association with the Acquired Immunodeficiency Syndrome (1985) (2)
HIV/AIDS primary care handbook (1995) (2)
THE EFFECT OF MENOPAUSAL STATUS, AGE, AND HIV ON NON-AIDS COMORBIDITY BURDEN AMONG U.S. WOMEN. (2022) (2)
Restriction of HIV-1 infection in sickle cell trait (2021) (2)
A Prospective Study of Exposure to Gender-Based Violence and Risk of Sexually Transmitted Infection Acquisition in the Women's Interagency HIV Study, 1995-2018. (2020) (2)
Self-Reported Sexually Transmitted Infections After Incarceration in Women with or at Risk for HIV in the United States, 2007-2017. (2021) (2)
Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy (2020) (2)
New developments in dideoxynucleoside antiretroviral therapy for HIV infection. (1991) (2)
Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine (2020) (2)
Immunodeficiency Virus-Infected Patients Zidovudine, and Didanosine in Human Population Pharmacokinetics of Nevirapine, (2013) (2)
Human ‑lymphoblastoid Interferon in the Treatment of Kaposi's Sarcoma, Internatl (1984) (2)
An Inhibitor in the Sera of Haitians with Acquired Immunodeficiency Syndrome of Lymphocyte Proliferation (1983) (1)
Decreased Natural Cell Mediated Cytotoxicity (NCC) to Cell‑Line K562 per Leu 11 Positive Cells in Acquired Immunodeficiency Syndrome (AIDS) (1985) (1)
Associations between population density and clinical and sociodemographic factors in women living with HIV in the Southern United States (2020) (1)
Microbial Translocation and Immune Activation in HIV-1 Infected Pregnant Women. (2018) (1)
Degree of polypharmacy and cognitive function in older women with HIV. (2022) (1)
Acquired Immunodeficiency Syndrome in Haitians: A Household Approach. Presented to the Cold Spring Harbor Special AIDS Meeting (1983) (1)
Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion (2017) (1)
Molecular profiling of breast and lung cancer in women with HIV reveals high tumor mutational burden (2021) (1)
Predicting relapse in acute asthma. (1984) (1)
Clinical trials: subgroup analyses. (1994) (1)
Clinical trials within the Florida Department of Corrections. (2000) (1)
Humoral Immune Abnormalities in Two South Florida Acquired Immunodeficiency Syndrome Risk Groups (1985) (1)
Peripheral artery disease and physical function in women with and without HIV (2021) (1)
Apparent False Positive ELISA Tests for HTLV/LAV Antibody (AB) and Polyclonal B cell Activation (PCBA) in Acquired Immunodeficiency Syndrome (AIDS) Risk Groups (1986) (1)
Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial (2003) (1)
White Blood Cell Counts, Lymphocyte Subsets, and Incident Diabetes Mellitus in Women Living With and Without HIV. (2019) (1)
IMMUNOLOGICAL STUDIES AND HTLV ANTIBODY STATUS OF MOTHERS OF INFANTS WITH AIDS (1984) (1)
Human T‑lymphotropic Virus Type III Infection Among Fema1e Prostitutes (1986) (1)
Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV (2020) (1)
Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus (2021) (1)
Delavirdine mesylate (DLV) in two and three drug combinations with zidovudine(ZDV)and didanosine (ddI), (ACTG261) (1997) (1)
Reduced Lymphocyte Cap Formation in Patients with AIDS and ARC. 3rd International Congress on AIDS (1987) (1)
Natural Cell Mediated Cytotoxicity (NCC) to Cell Line K562 per Leu 11 Positive Cell is Decreased in the Acquired Immunodeficiency Syndrome (1985) (1)
Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval–Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection (2019) (1)
Impacts of Medicaid Expansion on Health Insurance and Coverage Transitions among Women with or at Risk for HIV in the United States. (2022) (1)
T-cell immune dysregulation and mortality in women with HIV. (2021) (1)
Erratum: Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine (Archives of Internal Medicine (May 8, 1995) 155 (961-974)) (1995) (0)
Intersectionality of Socioecological Factors Associated With Cognitive Function Among Older Women With HIV in the United States: A Structural Equation Model Analysis Using Data From the Women's Interagency HIV Study (2022) (0)
Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV (2022) (0)
Prolonged Zidovudine Therapy: Confounded by Pneumocystis carinii Prophylaxis?-Reply (1990) (0)
Alterations in B cell compartment induced by aging and impact of HIV infection. (2017) (0)
Pharmacokinetics of Nelﬁnavir and Efavirenz in Antiretroviral-Naı¨ve, Human Immunodeﬁciency Virus-Infected Subjects when Administered Alone or in Combination with Nucleoside Analog Reverse Transcriptase Inhibitors (2005) (0)
Abstract 2580: Optimizing cervical cancer screening for HIV-infected women: A risk-based approach (2016) (0)
Associations between Antiretrovirals and Cognitive Function in Women with HIV (2020) (0)
Antiviral therapies for acquired immunodeficiency syndrome and human immunodeficiency virus type 1 infection (1990) (0)
Abstract 14374: Peripheral Artery Disease and Gait Speed in Women With and at Risk for HIV (2020) (0)
on Combination Antiretroviral Therapy Nonresponders among HIV-Infected Persons H1N1 Vaccine Responders from 2009 and IL-21 Secretion Distinguishes Novel Upregulation of IL-21 Receptor on B Cells (2011) (0)
HIV and Cardiac End-Organ Damage in Women: Findings from an Echocardiographic Study Across the United States. (2022) (0)
Group-Based Trajectory Modeling of Pulmonary Function in People Living with HIV (2021) (0)
Effect of Solvent Drag (1986) (0)
The effects of incarceration on sexually transmitted infections in women with or at risk for human immunodeficiency virus in the United States (2019) (0)
HIV disease: Pathogenesis and therapy (1991) (0)
Frequency of high grade squamous cervical lesions among women over age 65 years living with the human immunodeficiency virus. (2021) (0)
Estimating Point Exposure Effects on Count Outcomes with Observational Data (2022) (0)
Peripheral T follicular helper cells from H1N1/09 vaccine nonresponders fail to induce antigen-specific antibody production in vitro (2012) (0)
Chemoprophylaxis for Pneumocystis Carinii Pneumonia in AIDS-Reply (1988) (0)
Towards a Point‐of‐Care Test for Bacterial Vaginosis: Design and Development of a Rapid Test for Vaginolysin (2018) (0)
PD-1 and PDL-1 expression in patients with chronic HIV-1 infection: relationship to CD4%, immune activation and antiretroviral therapy (ART) (46.22) (2007) (0)
Long-Term Efﬁcacy, Safety, and Tolerability of Indinavir-Based Therapy in Protease Inhibitor–Naive Adults with Advanced HIV Infection (2003) (0)
A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX (2012) (0)
Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV (2020) (0)
Treatment with HIVID in combination with zidovudine (1992) (0)
The Effect of Zidovudine on Patient Subgroups-Reply (1992) (0)
HIV is associated with elevated FibroScan-AST (FAST) score. (2022) (0)
The Safety and Efficacy of Zidovudine (AZT) in the Treatment of Subjects with Mildly Symptomatic Human Immunodeficiency Virus Type 1 (HIV) Infection (2020) (0)
Hepatitis C Viremia and Diffusing Capacity for Carbon Monoxide in Women With and Without Human Immunodeficiency Virus (2023) (0)
Update on drug treatments for AIDS (1990) (0)
Overweight, Obesity, and Neuropsychological Performance: Results From the Women’s Interagency HIV Study (2021) (0)
Special Contributions HIV Pathogenesis and Prospects for Vaccine 4 From Talk to Action in Fighting AIDS in Developing 10 Countries (2001) (0)
Analysis of myopathy in a placebo-controlled zidovudine tiral (1996) (0)
P728 Correlates of syphilis in women living with and without HIV in the US women’s interagency HIV study (WIHS) (2019) (0)
977. The Prevalence and Burden of Non-AIDS Co-Morbidities in Women with or At-risk for HIV Infection in the United States (2019) (0)
Increase in the frequency of histoplasmosis caused by HIV infection (1997) (0)
Pulmonary Function Trajectories in People with HIV: Analysis of the Pittsburgh HIV Lung Cohort. (2022) (0)
Factors associated with syphilis seroprevalence in women with and at-risk for HIV infection in the Women’s Interagency HIV Study (1994–2015) (2021) (0)
Track B Clinical Science (2012) (0)
PP 1.15 – 00095 Proviruses persisting during the initial years of suppressive ART are relatively stable in terms of genetic diversity, clonal composition, and inferred integration date distribution (2022) (0)
Syndemic burden and systemic inflammation, HIV health status, and blood pressure among women with unsuppressed HIV viral loads in the Women's Interagency HIV Study. (2020) (0)
Control of HIV-1 Infection By Ferroportin Q248H Mutation (2019) (0)
Safety and eﬃ cacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial (2014) (0)
AIDS Clinical Trials Group Study Numbers (1995) (0)
Patient tolerance to interferon: clinical and laboratory assessments. (1986) (0)
Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997–2019 (2022) (0)
infection cycle entry and expansion in HIV-1 - IL-7 administration drives T cell (2011) (0)
PIII‐35 (2006) (0)
Socioeconomic, Psychosocial, and Clinical Factors Associated With Employment in Women With HIV in the United States: A Correlational Study (2021) (0)
Mechanisms linking gender-based violence to worse HIV treatment and care outcomes among women in the United States (2022) (0)
T-cell activation state differentially contributes to neuropsychiatric complications in women with HIV (2022) (0)
Effect of co‐administration of nelfinavir and covariates on the pharmacokinetics of indinavir in ACTG 388 trial (2004) (0)
Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV. (2022) (0)

This paper list is powered by the following services:

Other Resources About Margaret Fischl

en.wikipedia.org

What Schools Are Affiliated With Margaret Fischl?

Margaret Fischl is affiliated with the following schools:

University of Miami